Active Ingredient History

  • Now
Bardoxolone methyl is an experimental and orally-bioavailable semi-synthetic triterpenoid, based on the scaffold of the natural product oleanolic acid. Pre-clinical studies indicate that the compound acts as an activator of the Nrf2 pathway and an inhibitor of the NF-κB pathway. A phase 3 clinical trial evaluating bardoxolone methyl for the treatment of chronic kidney disease (CKD) was terminated in October 2012 after patients treated with the drug were found to have experienced a higher rate of heart-related adverse events, including heart failure, hospitalizations, and deaths.   Wikipedia

  • SMILES: CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@@]34C)C(=O)O
  • Mol. Mass: 491.67
  • ALogP: 6.29
  • ChEMBL Molecules:
More Chemistry
2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid methyl ester | 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid | bardoxolone | bardoxolone methyl | cddo | cddo-me | cddo methyl ester | methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate | nsc-713200 | rta-401 | rta 402 | rta-402


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue